



**Pascal Juillerat**

**Contact**

Pascal Juillerat

## Publications (11)

Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. *Therap Adv Gastroenterol* 2022; 15:17562848221074188.

Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. *Lancet Gastroenterol Hepatol* 2021; 7:128–140.

Schoepfer A, Henchoz S, Biedermann L, Schreiner P, Greuter T, Reinhard A, Senn J, Franke A, Burri E, Juillerat P, Simon H, Straumann A, Safraneva E, Godat S. Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. *Gastrointest Endosc* 2021; 94:912–919.e2.

Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, Mertens J, Roth R, Clottu A, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B, Swiss IBD Cohort Study Group. A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. *Br J Pharmacol* 2021; 178:3157–3175.

Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther* 2020; 53:138–149.

Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. *Digestion* 2020; 101 Suppl 1:16–26.

Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis* 2020

Misselwitz B, Juillerat P, Sulz M, Siegmund B, Brand S, Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. *Digestion* 2020; 101 Suppl 1:69–82.

Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med* 2019; 25:701.

Yilmaz B, Stelling J, Wiest R, Swiss IBD Cohort Investigators, Rogler G, Maillard M, Pittet V, Geuking M, Mueller C, Michetti P, Fournier N, Franc Y, Bravo F, Ramon C, Øyås O, Juillerat P, Macpherson A. Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med* 2019; 25:323–336.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safraneva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)